ECA Marcellus Trust I (ECTM)
OTCMKTS
· Delayed Price · Currency is USD
0.5600
-0.0100 (-1.75%)
May 20, 2025, 4:00 PM EDT
ECA Marcellus Trust I Revenue
ECA Marcellus Trust I had revenue of $1.28M in the quarter ending March 31, 2025, with 103.80% growth. This brings the company's revenue in the last twelve months to $2.83M, up 20.45% year-over-year. In the year 2024, ECA Marcellus Trust I had annual revenue of $2.18M, down -24.60%.
Revenue (ttm)
2.83M
Revenue Growth
+20.45%
P/S Ratio
3.61
Revenue / Employee
1.41M
Employees
2
Market Cap
10.21M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.18M | -709.58K | -24.60% |
Dec 31, 2023 | 2.88M | -8.74M | -75.18% |
Dec 31, 2022 | 11.62M | 5.33M | 84.63% |
Dec 31, 2021 | 6.30M | 4.59M | 269.63% |
Dec 31, 2020 | 1.70M | -2.44M | -58.92% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cyber App Solutions | 586.70K |
EXCO Resources | 394.03M |
Unit Corporation | 233.88M |
Pardee Resources Company | 50.63M |
Vantage Drilling International | 160.30M |
Granite Falls Energy, LLC | 409.95M |
Empire Diversified Energy | 3.64M |
CoJax Oil and Gas | 1.13M |
ECA Marcellus Trust I News
- 8 days ago - ECA Marcellus Trust I declares $0.052 dividend - Seeking Alpha
- 11 days ago - ECA Marcellus Trust I Announces Quarterly Distribution - Business Wire
- 3 months ago - ECA Marcellus Trust I Announces Quarterly Distribution - Business Wire
- 6 months ago - ECA Marcellus Trust I declares $0.005 dividend - Seeking Alpha
- 6 months ago - ECA Marcellus Trust I Announces Quarterly Distribution - Business Wire
- 6 months ago - Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel) - Business Wire
- 9 months ago - ECA Marcellus Trust I Announces There Will Be No Quarterly Distribution - Business Wire
- 11 months ago - Neurotech Pharmaceuticals, Inc. Receives Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a Treatment for Macular Telangiectasia Type 2 (MacTel) - Business Wire